Redeye gives its view following the announcement of positive interim data from the phase III study for Xlucane. The outcome in Xplore provides considerable validation of Xbrane's in-house capabilities and pipeline.
ANNONS
Redeye gives its view following the announcement of positive interim data from the phase III study for Xlucane. The outcome in Xplore provides considerable validation of Xbrane's in-house capabilities and pipeline.